RxDoctor Payments Data

Chalak Berzingi, MD

Interventional Cardiology · Roanoke, VANPI 1225073711

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (59.9%), food and beverage and education — rather than concentrated in one kind of arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2019 at $6,054 and has fallen 58.5% since, to $2,512 in 2025.

$14,084in general payments, 2019–2025

Across 112 payments — averaging $125.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$2K
  • Abiomed$2K
  • Edwards Lifesciences$2K
  • Teleflex LLC$1K
  • Penumbra, Inc.$966
  • plus $3K from 12 others
$10,220in research payments, 2019–2025

Across 5 payments — averaging $2044.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$10K

What the payments were for

  • Travel & lodging$8,43960%
  • Food & beverage$5,59540%
  • Education$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,084 in reported general payments places this provider in the 75th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$129,527
Medicare patients
322
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$71,894
JardianceEmpagliflozin47$43,461
EntrestoSacubitril/Valsartan17$21,219
Repatha SureclickEvolocumab11$8,276
BrilintaTicagrelor15$6,458
Isosorbide Mononitrate ErIsosorbide Mononitrate177$1,855
Atorvastatin Calcium208$1,673
Ezetimibe58$1,466
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,424
Metoprolol Succinate142$1,227
Rosuvastatin Calcium116$1,215
Amlodipine Besylate182$815
Nitroglycerin86$707
Losartan Potassium88$682
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide75$668

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →